Advertisement

Search Results

Advertisement



Your search for all items matches 439 pages

Showing 251 - 300


gynecologic cancers
gynecologic cancers

Extended-Field Intensity-Modulated Radiation Therapy for Cervical and Endometrial Cancers Does Not Increase Risk of Duodenal Toxicity

Women with cervical or endometrial cancer who require treatment to the para-aortic lymph nodes can safely receive extended-field intensity-modulated radiation therapy without increased risk of duodenal toxicity, according to a study by Xu et al in Practical Radiation Oncology. Extended-Field...

gynecologic cancers
gynecologic cancers

Addition of Bevacizumab to Standard Chemotherapy Does Not Improve Overall Survival in Newly Diagnosed Ovarian Cancer

Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Oza et al indicate no significant increase with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer. However, overall survival benefit of...

gynecologic cancers

ASCO Endorses ASTRO Guideline on Radiation Therapy After Surgery for Endometrial Cancer

The American Society of Clinical Oncology (ASCO) issued an endorsement of the American Society for Radiation Oncology (ASTRO) clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement was published by Meyer et al in the Journal of...

gynecologic cancers

Phase II Trial Shows Activity of mTOR Inhibitor Ridaforolimus in Advanced Endometrial Carcinoma

In a randomized phase II trial reported in the Journal of Clinical Oncology, Oza et al found that the mTOR inhibitor ridaforolimus was active in previously treated advanced endometrial carcinoma. Study Details In the open-label study, 130 patients with progressive disease after one or two lines...

issues in oncology
breast cancer
head and neck cancer
gynecologic cancers
issues in oncology
bladder cancer
issues in oncology

Immune Signaling Protein May Have Opposing Roles in Breast Cancer Development

Researchers at The University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers, as research now shows TLR4 can either promote or inhibit breast cancer cell growth depending on mutations in...

gynecologic cancers
issues in oncology

Single Dose of HPV-16/18 Vaccine May Prevent Cervical Cancer

A single dose of the recombinant human papillomavirus (HPV) bivalent (types 16 and 18) vaccine (Cervarix) appears to be as effective in preventing certain HPV infections as three doses, the currently recommended course of vaccination, concluded a study published by Kreimer et al in The Lancet...

gynecologic cancers
gynecologic cancers

ASCO 2015: IMGN853 Demonstrates Single-Agent Activity for Patients With Platinum-Resistant Ovarian Cancer

In a phase I trial, the investigational agent mirvetuximab soravtansine (IMGN853) was found to be active in patients with platinum-resistant ovarian cancer. ImmunoGen, Inc, announced the first clinical findings of this folate-receptor alpha (FRα)-targeting antibody-drug conjugate at the...

gynecologic cancers
gynecologic cancers
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Study Shows Nearly 15 Million Women Live Prohibitively Far From Access to Gynecologic Cancer Care

More than one-third of counties in the United States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. Although most of these “low-access” counties are...

gynecologic cancers
issues in oncology

Investigators Identify Gene That Prevents Immune Response in Ovarian Cancer

Researchers have identified a gene in dendritic cells that disables an effective immune response against ovarian cancer tumors. In preclinical studies, the researchers found that silencing this gene, XBP1, in dendritic cells restores their function and enhances T-cell antitumor immunity. XBP1 is...

gynecologic cancers
issues in oncology

Risk Algorithm Using Serial CA-125 Measurements Increases the Number of Screen-Detected Ovarian Cancers

As reported in the Journal of Clinical Oncology by Menon et al, findings in the United Kingdom Collaborative Trial of Ovarian Cancer Screening indicate that the number of screen-detected ovarian cancers is doubled by using the risk of ovarian cancer algorithm (ROCA) with serial CA-125 measurements...

colorectal cancer
solid tumors
gynecologic cancers

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

A phase II study identified the first genomic marker—mismatch repair deficiency—to predict clinical benefit of immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab (Keytruda). Among 50 patients with colorectal cancer, 62% of the 25 patients with mismatch...

gynecologic cancers
gynecologic cancers

UK Trial Shows Neoadjuvant Platinum-Based Chemotherapy Noninferior to Adjuvant Chemotherapy in Advanced Ovarian Cancer

In the UK phase III CHORUS trial reported in The Lancet, Kehoe et al found that a strategy of three cycles of platinum-based chemotherapy followed by delayed surgery and three additional cycles of chemotherapy was associated with overall survival noninferior to that achieved with surgery followed...

gynecologic cancers

Second-Line Dovitinib Shows Some Activity in FGFR2-Mutant and FGFR2-Nonmutant Advanced Endometrial Cancer

In a phase II study reported in The Lancet Oncology, Konecny et al found that the multi–tyrosine kinase inhibitor dovitinib appeared to delay progression in some patients as second-line treatment in fibroblast growth factor receptor 2 (FGFR2)-mutant and -nonmutant advanced or metastatic...

breast cancer
gynecologic cancers
issues in oncology

Women With Inherited KRAS-Variant Mutation May Be at Increased Breast Cancer Risk Due to Acute Estrogen Withdrawal

Researchers at UCLA Jonsson Comprehensive Cancer Center have discovered that for women with a relatively common inherited mutation, known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact breast cancer biology. Scientists also found that women with...

breast cancer
gynecologic cancers
colorectal cancer
gynecologic cancers
prostate cancer
issues in oncology

American College of Physicians Offers Advice on High-Value Screening in Five Cancers

To provide guidance on high-value cancer care screening strategies, the American College of Physicians (ACP) recently reviewed clinical guidelines issued by various medical organizations for screening strategies in five common cancers for asymptomatic, average-risk adults. The five cancers focused...

gynecologic cancers
solid tumors
gynecologic cancers
head and neck cancer
issues in oncology

Nine-Valent HPV Vaccine Protects Against 80% of Cervical Cancers

The new nine-valent human papillomavirus (HPV) vaccine (Gardasil 9) can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. Additionally, the new vaccine, which includes seven cancer-causing...

gynecologic cancers
gynecologic cancers

Combining Ixabepilone and Bevacizumab Appears Safe and Effective in Recurrent Uterine and Ovarian Cancers

In patients with recurrent/persistent uterine or ovarian/primary peritoneal/fallopian tube cancers, ixabepilone (Ixempra), especially with the addition of biweekly bevacizumab (Avastin), appears to be safe and effective, according to a study by Roque et al in Gynecologic Oncology. Further...

gynecologic cancers
gynecologic cancers
issues in oncology

Frequent Aspirin Use Reduces Risk of Cervical Cancer by Nearly Half

Long-term and frequent use of aspirin is associated with significantly decreased risk of cervical cancer, according to a study led by researchers at Roswell Park Cancer Institute and published by Friel et al in the Journal of Lower Genital Tract Disease. Study Findings Aspirin use was associated...

gynecologic cancers
sarcoma

American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women

The American College of Physicians (ACP) released its clinical advice for cervical cancer screening in asymptomatic, average-risk women 21 years or older. Women at average risk are defined as those with no history of a precancerous lesion (cervical intraepithelial neoplasia grade 2 or a more severe ...

gynecologic cancers
gynecologic cancers

Phase II Study Shows Addition of Pazopanib to Paclitaxel Improves Progression-Free Survival in Platinum-Resistant/Refractory Advanced Ovarian Cancer

In an Italian randomized phase II trial reported in The Lancet Oncology, Pignata et al found that the addition of the antiangiogenic multikinase inhibitor pazopanib (Votrient) to weekly paclitaxel significantly improved progression-free survival in patients with platinum-resistant/refractory...

gynecologic cancers
issues in oncology

Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects

A new surgical approach that removes the fallopian tubes—while sparing the ovaries—may provide premenopausal women at high risk for ovarian cancer, particularly those with BRCA1/2 mutations, with a surgical option that minimizes cancer risk while also reducing some of the negative...

breast cancer
gynecologic cancers
prostate cancer
issues in oncology
solid tumors

AACR 2015: New PARP Inhibitor Combination Shows Early Promise for a Wide Range of Cancer Patients

A combination of two molecularly targeted drugs, olaparib (Lynparza) and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2-mutation status, according to data from the...

breast cancer
gynecologic cancers
issues in oncology

AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes

Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...

gynecologic cancers
head and neck cancer
issues in oncology

AACR 2015: HPV Vaccine Provides Protection at Multiple Sites, Even Among Some Previously Exposed Patients

Vaccination of women aged 18 to 25 with the human papillomavirus (HPV) vaccine resulted in strong protection against future infection at three anatomic sites among women without prior HPV exposure and may still offer some protection in those with evidence of prior exposure. These findings were...

palliative care
gynecologic cancers
pancreatic cancer
solid tumors

AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers

Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...

gynecologic cancers
head and neck cancer
issues in oncology
cost of care

Increasing Number of Boys Vaccinated Against HPV Could Protect More People at the Same Price

Public health programs that devote a portion of their funding to encourage more boys to be vaccinated against human papillomavirus (HPV)—rather than merely attempting to raise coverage among girls—may ultimately protect more people for the same price, a study from Duke University...

gynecologic cancers

Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells

As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...

breast cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Risk of Breast and Ovarian Cancers May Differ by BRCA1/2 Mutation Type

Women who have inherited mutations in BRCA1 or BRCA2 (BRCA1/2) have an increased risk of breast and ovarian cancers. However, little has been known about how cancer risks differ by BRCA1/2 mutation type. In a study involving more than 31,000 women who are carriers of disease-associated mutations...

gynecologic cancers

FDA Grants Breakthrough Therapy Designation to Rucaparib in Advanced Ovarian Cancer With BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Clovis Oncology’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with...

issues in oncology
gynecologic cancers

Nocturnal Cortisol Levels May Provide a Noninvasive Biomarker of Ovarian Cancer Severity

Elevated nocturnal cortisol levels prior to surgery in patients with ovarian cancer were associated with shorter survival time, according to a study by Schrepf et al in Psychoneuroendocrinology. Thus, night-time cortisol levels may prove to be a noninvasive biomarker of ovarian cancer disease...

gynecologic cancers

Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer

In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...

gynecologic cancers
gynecologic cancers

Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers

According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...

gynecologic cancers
issues in oncology

Sentinel Lymph Node Mapping Identifies Positive Lymph Nodes in Women With High-Risk Endometrial Cancer

In a study of women with high-grade endometrial cancer, researchers at The University of Texas MD Anderson Cancer Center found sentinel lymph node mapping accurately identified all women with node-positive, high-risk endometrial cancer, when prospectively compared to a complete pelvic and...

gynecologic cancers
gynecologic cancers

Addition of Bevacizumab to Chemotherapy Extends Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer

In a phase III study of women with ovarian cancer, researchers found that the addition of bevacizumab (Avastin) to standard chemotherapy extended median overall survival by 5 months compared to standard chemotherapy alone. The bevacizumab combination was also associated with a significant...

gynecologic cancers

New Surgical Algorithm Results in Improved Complete Resection Rates in Advanced Ovarian Cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor—a milestone strongly tied to improved chances of survival. The researchers describe...

gynecologic cancers

Age-Stratified Predictive Model May Provide Surgical Guidelines for Uterine Leiomyomas

A study by Brohl et al investigating the case incidence of unexpected uterine sarcoma following surgery for presumed benign leiomyoma (fibroids or myomas) has found that the risk of unexpected uterine sarcoma varies significantly across age groups, with a more than fivefold difference between the...

gynecologic cancers
sarcoma

No Benefit of Adding Bevacizumab to First-Line Gemcitabine-Docetaxel in Metastatic Uterine Leiomyosarcoma

In a phase III NRG Oncology/Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Hensley et al found no benefit of adding bevacizumab (Avastin) to first-line gemcitabine-docetaxel in patients with metastatic uterine leiomyosarcoma. Study Details In this...

gynecologic cancers
gynecologic cancers

Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer

In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...

gynecologic cancers

Oral Bisphosphonate Use Reduces Risk of Postmenopausal Endometrial Cancer

Bisphosphonate use for treatment or prevention of osteoporosis in postmenopausal women has been associated with a reduced risk of breast cancer, including in a study in the Women’s Health Initiative (WHI) population. In a WHI study reported in the Journal of Clinical Oncology, Newcomb et al...

gynecologic cancers
gynecologic cancers

Meta-Analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormone Therapy

In a study reported in The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer found that use of menopausal hormone therapy was associated with an increased risk of ovarian cancer, with the risk being highest among current users. The study consisted of meta-analyses of...

gynecologic cancers

Human Reovirus Formulation Receives FDA Orphan Drug Designation for Fallopian Tube Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of fallopian tube cancer. The designation was granted on the basis of the company's December 2014 application for ...

gynecologic cancers

12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility

Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...

gynecologic cancers

Early Study Suggests Olaparib May Be Effective in Ovarian Cancers Expressing High Levels of POLQ

Last December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in the treatment of advanced ovarian cancer in women with BRCA1 or BRCA2 gene mutations. Now, a laboratory study by Ceccaldi et al has found that the drug may also be effective in breast and ovarian tumors that...

gynecologic cancers
issues in oncology

Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer

Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...

gynecologic cancers

FDA Grants Orphan Drug Designation to Human Reovirus Formulation for the Treatment of Ovarian Cancer

Oncolytics Biotech, Inc, a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its proprietary formulation of the human reovirus...

gynecologic cancers
gynecologic cancers

Adding Sorafenib to Standard Therapy of No Benefit in Advanced Ovarian Cancer, Study Reveals

In a study of women with stage III/IV epithelial ovarian cancer, the addition of sorafenib (Nexavar) to traditional paclitaxel/carboplatin therapy resulted in no greater efficacy and increased toxicity, according to a report by Hainsworth et al in Cancer Medicine. The investigators suggested that...

gynecologic cancers
issues in oncology

No Reduction in Quality of Life With Addition of Bevacizumab to Chemotherapy in GOG 240 Trial in Advanced Cervical Cancer

The phase III Gynecologic Oncology Group (GOG) 240 trial showed that the addition of bevacizumab (Avastin) to chemotherapy prolonged survival in patients with advanced cervical cancer. An analysis reported in The Lancet Oncology by Penson et al showed no reduction in quality of life among patients...

gynecologic cancers

Phase II Study Shows Activity of Everolimus and Letrozole in Recurrent Endometrial Carcinoma

Interaction of the estrogen receptor and PI3K/AKT/mTOR pathways and the finding of resistance to hormonal therapy mediated by PI3K activation suggest a benefit of adding an mTOR inhibitor to hormonal treatment in endometrial carcinoma. In a phase II study reported in the Journal of Clinical...

gynecologic cancers
issues in oncology

Researchers Pinpoint Two Genes That Trigger Most Severe Form of Ovarian Cancer

Researchers at University of North Carolina School of Medicine have created the first mouse model of the most aggressive form of ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Led by Terry Magnuson, PhD, the Sarah Graham Kenan Professor and Chair ...

issues in oncology
breast cancer
gynecologic cancers
issues in oncology

Next-Generation Sequencing Uncovers Potential Genetic Drivers of Rare Breast Tumors

A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of phyllodes tumors, a rare type of breast tumor. The study offers the first comprehensive analysis of the molecular alterations at work in these tumors, according to Cani...

Advertisement

Advertisement



Advertisement